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Hydrogen sulﬁde (H2S) has emerged as a critical mediator of multiple physiological processes in
mammalian systems. The pathways involved in the production, consumption, and mechanism of action
of H2S appear to be sensitive to alterations in the cellular redox state and O2 tension. Indeed, the
catabolism of H2S through a putative oxidation pathway, the sulﬁde quinone oxido-reductase system,
is highly dependent on O2 tension. Dysregulation of H2S homeostasis has also been implicated in
numerous pathological conditions and diseases. In this review, the chemistry and the main physiolo-
gical actions of H2S are presented. Some examples highlighting the cytoprotective actions of H2S within
the context of cardiovascular disease are also reported. Elucidation of the redox biology of H2S will
enable the development of new pharmacological agents based on this intriguing new redox cellular
signal.
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Hydrogen sulﬁde (H2S); a toxic gas, is endogenously produced,
bioactive, and contributes to numerous physiological functions in
mammalian systems. Studies support the possibility that H2S has
therapeutic potential for treating multiple diseases including
cardiovascular diseases. For example, experimental animal studies
show that H2S may be effective in treating atherosclerosis and
protecting against ischemia-reperfusion injury [1–3]. Interest in
the cytoprotective actions of H2S has grown since the discovery
that it can induce a hypometabolic state characterized by
decreased O2 consumption, heart rate, and body temperature in
non-hibernating rodents [4]. Although not discussed in this review,
H2S-dependent hypometabolism is an O2-dependent phenom-
enon [5]. The proposed mitochondrial and signaling actions of
H2S make this molecule an attractive intervention for preventing
and treating diseases and trauma-associated injuries. In this review
article, we provide an overview of H2S redox biology as it relates to
the biological and pharmacological actions of this interesting new
signaling molecule in mammalian systems.2. Historical beneﬁts of H2S
The ancient Greeks, Egyptians, and Romans regularly bathed in
natural sulfur springs as treatments for disease [6]. Depending on
the microbiota and oxygen content, sulfur springs typically
contain H2S concentrations ranging from 1 to 500 mM [7] with
anti-inﬂammatory, anti-bacterial, vasodilatory, and anti-fungal
properties attributed to the sulfur-containing water [8]. Epide-
miological studies report that a diet rich in organosulfur species is
associated with longevity and decreased morbidity [9]. Members
of the Allium genus (garlic and onions), which contain organosul-
fur compounds have a well-documented history of health beneﬁts
[10]. Indeed, garlic-derived compounds such as diallyl trisulﬁde
release H2S in the presence of cellular reductants like glutathione
(GSH) [11]. Populations that consume garlic regularly have low
blood pressure, low cholesterol, and less vascular disease [12].
While administration of exogenous sulfur-containing compounds
shows strong promise as therapies, H2S is also endogenously
produced in many different human tissues.3. Endogenous production of H2S
In the early 1990s, it was discovered that H2S is enzymatically
produced by two cytosolic enzymes; cystathionine b-synthase
(CBS) and cystathionine g-lyase (CGL) [13,14]. Seminal work of
Abe and Kimura showed, for the ﬁrst time, that H2S enhances
long-term potentiation in the hippocampus [15]. Speciﬁcally, they
demonstrated that H2S was produced by CBS and that exogenous
H2S enhanced NMDA receptor-mediated responses. Since then
many studies have shown that CBS and CGL are expressed in
human tissues with H2S contributing to physiological and patho-
physiological processes (Table 1). In addition to CBS and CGL,
there are other enzymes that produce H2S with several utilizingTable 1
Biological and therapeutic actions of H2S are O2-dependent.
Biological context Low O2
Inﬂammation Anti-inﬂammatory: IL-10; k IL-6, IC
Vasoactivity Vasodilatory: m KATP channel condu
Angiogenesis Pro-angiogenic: VEGF, Hif1-a
Respiratory inhibition Higher [H2S] results in more inhibit
Ischemia-reperfusion Ischemic tissue has higher [H2S]: mcysteine as a substrate. The enzyme 3-mercaptopyruvate S-
transferase (3-MST) is found in mitochondria and cytosol and
produces H2S [16]. Several H2S producing enzymes are pyridoxal-
50-phosphate (PLP) dependent enzymes [17]. Moreover, other
sulfur-containing amino acids, such as cystine and homocysteine,
can be metabolized to generate H2S. The enzymatic mechanisms
of H2S production are shown in Fig. 1. Many of these enzymes
participate in the cellular sulfur cycle and have multiple enzy-
matic activities, including H2S generation. Because the concentra-
tion of reduced sulfur species has an effect on many cellular
processes [18], the activity of these enzymes is tightly regulated.
Much of this regulation is linked to substrate availability [19].
Moreover, these are redox-sensitive enzymes, which exhibit
increased activity under oxidative conditions [20]. Considering
that H2S; a reductant, is a product of these enzymes, it is
conceivable that enzymatic activity may also be subject to negative
feedback regulation. Finally, work by Wang et al. suggests that
under certain conditions, such as oxidative stress, H2S-producing
enzymes translocate from the cytosol to mitochondria [21]. This
dynamic regulation bolsters the argument that H2S may function
as a redox signaling molecule.4. Catabolism of H2S
Several regulated and unregulated non-enzymatic processes
participate in H2S catabolism. These pathways maintain in vivo
H2S concentrations, most likely, in the nM to low mM range. H2S
can react with heme proteins in mitochondria and therefore H2S
can function as a mitochondrial respiratory toxicant [22,23]. Fatal
industrial accidents have been documented in individuals exposed
to high concentrations of H2S gas (e.g., 41000 pm) [24]. Therefore,
the toxicological proﬁle of H2S has been well-studied and docu-
mented [24]. The mechanism of toxicity is through the binding of
H2S to cytochrome c oxidase (CcO) mediating respiratory inhibition
[22]. However, this interaction is complex and poorly understood
because H2S can act as both an inhibitor and an electron donor for
CcO [25]. H2S binds to the oxidized states of the heme a-a3
binuclear center, resulting in the reduction of the heme molecules
[26]. Excess H2S can also reduce CuB [27]. While the stoichiometry
may vary, Cooper and Brown reported that 3 molecules of H2S bind
per inhibited CcO [28]. In this inhibitory reaction, H2S is oxidized to
sulfane sulfur and this is coupled to consumption of molecular O2
[28]. Unlike nitric oxide (dNO), the inhibition of CcO by H2S is
noncompetitive with O2 [27,29]. In addition, H2S can also directly
reduce the electron carrier cytochrome c producing the one
electron oxidation product, the thiyl radical (dSH) [28].
Rhodanese, a mitochondrial sulfur transferase enzyme, cata-
lyzes the oxidation of H2S [30]. It is one part of three enzymatic
activities characterized as a major pathway for H2S catabolism.
This pathway consists of a sulﬁde quinone oxido-reductase (SQR),
a sulfur dioxygenase, and the sulfur transferase enzyme rhoda-
nese (Figs. 2 and 3). H2S reduces the external disulﬁde on the SQR
to form a thiol (RSH) and a perthiol (RSSH). This two electron
oxidation of H2S reduces the FAD prosthetic group, which uses
ubiquinone (Q) as an electron acceptor [31] The second sulfurHigh O2
AM Pro-inﬂammatory: m NF-kB, TNF-a
ctance Vasoconstrictive
No effect
ion O2 acts as an H2S antagonist: mSOx
ito KATP, ARE genes Unknown
CBS
CBS
+
CGL
+
CBS
+
CGL
3-MST
CAT
CGL
Fig. 1. The enzymatic production of H2S. The two primary enzymes responsible for H2S production, cystathionine-g-lyase (CGL) and cystathionine-b-synthase (CBS), are
found in the cytosol. CBS catalyzes the ﬁrst step in H2S production through the transsulfuration of homocysteine to cystathionine. CGL in an elimination reaction catalyzes
the formation of cysteine and a-ketobutyrate. Cysteine is the substrate from which H2S is directly produced either through elimination (CGL) or b-replacement (CBS).
Cysteine amino transferase (CAT) catalyzes the formation of 3-mercaptopyruvate, a substrate for the mitochondrial enzyme 3-mercaptopyruvate-S-transferase (3-MST).
3-MST can directly produce H2S, albeit at lower levels than CBS and CGL, in mitochondria.
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by a sulfur dioxygenase enzyme encoded by the gene ETHE1,
consuming O2 and H2O to form sulﬁte (SO3
2). While the protein
responsible for this enzymatic activity is not known, the ETHE1
gene encoding the protein has been identiﬁed. Mutations in this
gene cause a buildup of H2S leading to ethylmalonic encephalo-
pathy [32,33]. Rhodanese then transfers a sulfane sulfur to sulﬁte
to form thiosulfate (S2O3
2) [34]. This proposed oxidation path-
way, in close proximity to CcO, functions as a major clearance
pathway of cellular H2S. H2S can also be oxidized by non-
mitochondrial heme proteins such as hemoglobin (Hb) and
myoglobin [35]. H2S will reduce the ferric iron in met-Hb,
restoring the oxygen binding abilities of the protein [36]. At high
concentrations of H2S, sulf-Hb can also be formed from oxy-Hb
[37]. While displaying very weak afﬁnity for O2, sulf-Hb can still
deliver O2, albeit with no cooperativity [38]. As a result, the
bioavailability of H2S, whether in the context of steady state
in vivo concentrations or exogenously administered, is dictated by
the O2 concentration. Therefore, O2 can be considered an H2Santagonist, accelerating its oxidation and attenuating its biologi-
cal actions. The effect of O2 on H2S concentration is both direct
and indirect. The spontaneous reaction of H2S with O2, while
slow, can cause an appreciable decrease in the H2S concentration.
Thus, tissues with relatively high O2 concentrations (e.g., alveolar
epithelium) may have less H2S compared to tissues that are in a
lower O2 environment (e.g., centrilobular region of liver). This has
implications in pathological states of hypoxia such as ischemia-
reperfusion, where the availability, and thus the signaling effects
of H2S may be augmented. Furthermore, O2 concentration can
indirectly affect H2S concentration through changes in the redox
state of heme proteins. Proteins such as Hb will react with H2S at
different rates depending on the redox status of the hemes. For
example, H2S will react more rapidly with met-Hb (Fe
þ3) than
with deoxy-Hb (Feþ2) [36].
Because H2S is a nucleophile, it can also react with electro-
philic lipids [39]; and the thiolate anion, HS , can also reduce
disulﬁde bonds (Fig. 2) [40]. Indeed, the exfoliation of skin cells in
hot sulfur springs is due to H2S reducing the structural disulﬁde
H2S
Sulfide Quinone 
Reductase
SOx
S
S
S
HS
HS
O2˙OH 
O2˙-
ONOO-
thiol-S-
methyltransferase
H3C―SH
Sulfur Dioxygenase
Rhodanese
N
N
N
N
Fe
Fig. 2. Proposed pathways of H2S removal in mammalian cells. The physiological
steady-state concentration of H2S in vivo is believed to be maintained in the sub-
micromolar range. This steady state concentration is established by the produc-
tion pathways shown in Fig. 1 and the proposed consumption pathways shown
within this ﬁgure. H2S will react non-enzymatically with many biomolecules such
as reactive oxygen and nitrogen species, electrophilic lipids like 4-hydroxy-2-
nonenal, free heme, and disulﬁde bonds to form a thiol and perthiol. The
catabolism of H2S can also be catalyzed enzymatically by the sulﬁde quinone
oxido-reductase system (SQR) comprised by sulfur dioxygenase, rhodanese, and
sulfur quinone reductase.
III IV
H+ H+
Q
½ O2 H2O
SQR
ETHE1 Rhod
2 e-
2 e-
S0
S0
H2O + O2
H2SO3
H2S2O3
2 H2S
Inter-membrane space
Matrix
SOx S¯
Hypoxia?
?
Fig. 3. The oxidation of H2S by the sulﬁde quinone oxido-reductase system in
mitochondria. H2S reduces the disulﬁde composed of the vicinal thiols on the
sulﬁde quinone reductase (SQR) forming a thiol and a perthiol. The second sulfur
atom on the perthiol, the sulfane sulfur (S0), is the substrate for both the sulfur
transferase enzyme, rhodanese, and the sulfur dioxygenase enzyme encoded by
the gene ETHE1. Rhodanese catalyzes the formation of thiosulfate (S2O3
2) from
sulﬁte (SO3
2) and S0. ETHE1 catalyzes the formation of SO3
2. The reduced SQR can
then transfer electrons into the ubiquinone (Q) pool, thus coupling the oxidation
of H2S to electron transfer, H
þ pumping, and ultimately ATP synthesis.
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harmful at high concentrations, the reduction of external disulﬁde
bonds by H2S may, in some instances, reverse a deleterious post-
translational protein modiﬁcation. Although still contentious, the
S-sulfhydration of cysteine residues may represent an important
sink for free H2S [41]. In theory, H2S can also reduce higher thiol
oxidation states such as S-nitrosothiols and sulfenic acids [42].
H2S can also be methylated by the cytosolic enzyme thiol-S-
methyltransferase to form methane thiol. As with virtually allmolecules, H2S can react with other free radical species, as well
as, a number of non-radical reactive oxygen (ROS) and nitrogen
(RNS) species (Fig. 2) [43]. Many of the oxidized sulfur species as
well as sulfur-centered radicals formed are less reactive than their
oxygen-containing counterparts [44]. One of the most important
oxidants responsible for the catabolism of H2S is O2. In the
presence of molecular O2 and redox active metals, H2S will
spontaneously oxidize [45]. In an oxygenated biological medium,
metalloproteins catalyze H2S oxidation. This makes O2 tension a
critical methodological consideration when conducting biologi-
cally relevant experiments.5. Measurement of H2S in mammalian samples
As the ﬁeld of H2S continues to grow, accurate measurement of
H2S in biological samples is critical for proper understanding of its
biochemistry and identifying its key physiological roles. Early studies
reported endogenous H2S concentrations in mammalian tissues to be
approximately 160 mM [46]. However, when considering that the Ki
of CcO for H2S is 0.2 mM [28] it is unlikely that free H2S exists at high
mM concentrations. Older methods relied on inducing large pH shifts
during sample preparation followed by capturing the released sulﬁde
anions with metals such as silver or zinc [47] and then measuring
these complexes by spectrophotometry or chromatography [46]. One
problem with these methods is that they liberate multiple acid-labile
sulfur species, including those in Fe–S centers, giving artiﬁcially high
values. Recently, the mono-bromobimane assay has been reﬁned to
exclude sulfur species other than free H2S [47]. As techniques
improve, the reported concentrations of H2S in mammalian samples
have decreased from the 100–200 mM range to less than 500 nM [48].
Other techniques, including polarography, have measured H2S con-
centrations in mouse blood in the sub-mM range (Stein et al.,
unpublished data). These lower values are more plausible when
considering the inhibitory potential of H2S for heme-containing
proteins, in addition to, parallels between H2S and other signaling
molecules such as dNO and carbon monoxide (CO). It is also
important to note that whole tissue or cell lysate measurements of
H2S overlook compartmental differences in H2S concentrations and
thus likely underestimate the effective localized concentrations of H2S
in vivo. Because the technology required to accurately measure H2S
on the sub-cellular level is unavailable, it is important to recognize
these limitations when considering physiologically relevant levels
and reactions of H2S.6. Biological roles of H2S
Like dNO and CO, H2S is produced in many different cell types
and can easily diffuse without the need for transporters. There-
fore, it is not surprising that H2S has diverse biological actions
(Fig. 4). Important factors that determine the biological actions of
H2S include, but are not limited to, differences in the solubility of
H2S in aqueous vs. lipid phases, proximity of the target to H2S-
detoxifying enzymes, heme redox state, and inter- and intracel-
lular differences in O2 tension.7. Vasoactivity
One of the ﬁrst physiological roles that prompted investigators to
regard H2S as the ‘‘third gaseous signaling molecule’’ was vasodila-
tion. In 2001, Zhao et al. showed that H2S decreased blood pressure in
rats in vivo and caused vascular smoothmuscle cell (VSMC) relaxation
in vitro [49]. H2S-mediated vasodilation has also been shown in the
ileum of the gastrointestinal tract and the vas deferens [50]. Addition-
ally, others have shown that transgenic mice deﬁcient in CBS are
Fig. 4. Interaction of O2 and H2S on physiological outcomes. H2S plays a role in
many physiological processes. Additionally, it is capable of acting as a therapeutic
agent. The concentration of H2S, whether endogenously produced or exogenously
administered, will dictate the outcome. This can be beneﬁcial at low and
intermediate concentrations or harmful at high concentrations. High O2 can
reverse many of the beneﬁcial roles of H2S seen at lower O2 concentrations,
resulting in, for example, vasoconstriction rather than vasodilation. Additionally,
under hypoxic and normoxic conditions, H2S promotes angiogenesis. However, at
higher concentrations of both O2 and H2S, an inhibition of cellular proliferation is
seen. H2S has a narrow therapeutic window within which it is cytoprotective. At
high concentrations it can be pro-apoptotic and pro-inﬂammatory. Finally, the
larger doses of H2S necessary to induce a hypometabolic effect, can, if pushed
further, result in cardiac and respiratory toxicity.
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by increasing the conductance of adenosine triphosphate (ATP)
sensitive potassium channels (KATP). Furthermore, the speciﬁc mole-
cular targets of H2S were shown to be cysteine 6 and 26 of the
extracellular portion of the rvSUR1 subunit of the KATP channel
complex [52]. These vicinal thiols form a disulﬁde bond, which H2S
reduces, increasing channel conductance. However, the vasodilatory
effect of H2S is highly O2-dependent as supra-physiological levels of
O2 (200 mM) cause H2S-induced vasoconstriction [53]. Recently,
conﬂicting reports have emerged showing that the contribution of
the KATP channels to H2S-induced vasodilation is minimal and that
vasodilation is due to metabolic inhibition (i.e., decrease in ATP),
intracellular pH changes, and modulation of Cl/HCO3 channels [54].
There are several methodological differences including O2 tension,
pre-contraction agent, vessel type, and the type of sulﬁde-based
chemical used, which may account for discrepancies among experi-
mental studies. There are also indications that H2S may act through
dNO to stimulate vasodilation. Studies suggest that H2S liberates
dNO
from S-nitrosothiols [55]. Others show that endothelial denudation
and nitric oxide synthase (NOS) inhibitors shift the dose–response
curve to the right [56]. However, H2S increases eNOS phosphorylation
and subsequent dNO production in an Akt-dependent manner [57].
While the mechanism(s) responsible for vasodilation remain unclear,
the role of H2S as a vasodilator is accepted and there is great interest
in employing H2S-releasing agents as therapies to treat hypertension.8. Angiogenesis
H2S can cause cell proliferation and migration [58,59]; how-
ever, there appears to be a narrow concentration range of the
proliferative effect, below which no effect is seen and abovewhich there is anti-proliferation and H2S cytotoxicity [60]. In cell
culture experiments, low micromolar concentrations of H2S
increase endothelial cell number, proto-vessel formation, and cell
migration [58]. Chicken chorioallantoic membranes, an in vivo
model of angiogenesis, display increased branching and lengthen-
ing of blood vessels in response to 48 h incubation with H2S [59].
Additionally, aortic tissue isolated from transgenic mice lacking
CSE, the primary H2S-producing enzyme in the endothelium,
exhibit marked decreases in angiogenesis [59].
The mechanism of H2S-induced angiogenesis operates through
several pathways, including activation of ATP-sensitive potassium
(KATP) channels [49]. Papapetropoulos et al. showed that treat-
ment of endothelial cells with the KATP channel inhibitor glib-
enclamide reduced cell migration, which was accompanied by
decreased H2S-induced p38 and heat shock protein 27 (Hsp27)
phosphorylation [59]. Additionally, H2S can stimulate angiogen-
esis through phosphatidylinositol 3-kinase (PI3K) and Akt activa-
tion [61]. H2S can also activate hypoxia inducible factor-1a (HIF-
1a) and thus increase expression of vascular endothelial growth
factor (VEGF) [62]. Conversely, VEGF-stimulated angiogenesis is
suppressed in CSE knockout mice [58].
Endogenous H2S production is known to be upregulated
during wound healing [63]. Topically applied H2S accelerates
wound closure and healing [59]. Angiogenesis is very important
in both acute and chronic ischemia as poorly vascularized tissue
will lose function and possibly become necrotic. In models of
chronic hind limb ischemia, sodium hydrosulﬁde (NaHS)
increased capillary formation and blood ﬂow [64]. Similar results
were found in chronically ischemic hearts with improvements in
cardiac function following H2S treatment [65]. These studies
indicate that endogenous H2S is crucial in physiological angiogen-
esis and that those capabilities can be employed in disease
treatment.9. Inﬂammation
Several studies report that H2S is a mediator of inﬂammation
[66–69], while others report that H2S ameliorates inﬂammatory
sequelae [70–72]. These studies are likely in conﬂict because
different models of inﬂammation, H2S production inhibitors, H2S
‘‘donors’’, and different O2 tensions were used for experiments.
Using NaHS, several groups have shown that H2S augments
neutrophil migration and adhesion, nociception, and increases
endotoxemia [66,67,73]. This is likely because upon application
NaHS ‘‘releases’’ all its H2S instantly, which may be pro-
inﬂammatory in some cases. This is in contrast to the much
slower kinetics and magnitude of endogenous H2S production.
Moreover, a burst of H2S may alter
dNO homeostasis as well,
decreasing its bioavailability through direct reactions and through
inhibition of NOS [74]. Regarding endogenous production, some
groups report that CSE is upregulated during lipopolysaccharide
(LPS)-induced endotoxemia and that pharmacological inhibition
of CSE attenuated inﬂammation [68,69]. Whiteman et al. high-
lighted differences between using rapid release of high concen-
trations of H2S vs. using slow-releasing donor compounds, which
more closely mimic endogenous production. They showed that a
slow-releasing H2S donor dose-dependently inhibited LPS-
induced inﬂammation by decreasing the pro-inﬂammatory med-
iators IL-1b, IL-6, TNF-a, and PGE2 [74]. Additionally, they showed
an increase in the anti-inﬂammatory cytokine IL-10 in an NFkB-
dependent mechanism [75]. This report is similar to others that
show H2S-dependent inhibition of
dNO and TNF-a through p38
inhibition; a known downstream target of H2S [76]. In contrast to
[68], which used a non-speciﬁc PLP-dependent enzyme inhibitor,
propargylglycine (PAG), others have used the CSE inhibitor
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kocyte adhesion to the endothelium, indicating some off-target effects
of PAG and that endogenous H2S is anti-inﬂammatory [70]. Like
vasodilation, the anti-inﬂammatory effects of H2S appear to be KATP
channel-dependent with glibenclamide reversing the inhibitory
effects of H2S on leukocyte adhesion [71]. Although there are
conﬂicting reports regarding the role of H2S in inﬂammation, com-
mon themes have emerged that shed light on the reasons for these
disparate results. H2S donor compounds with slow release kinetics
that mimic endogenous production appear to ameliorate inﬂamma-
tion. This is contrasted against the apparent pro-inﬂammatory
potential of low purity sulﬁde salts, which immediately dissociate
in solution to rapidly deliver large doses of H2S. As with vasoactivity,
the role of H2S in inﬂammation is redox sensitive and this becomes
important when impure sulﬁde salts are used in experiments. In
addition to sulﬁde, these salts contain oxidized sulfur species
such as sulfates, sulfenic acid, and sulfonates. In contrast to H2S,
these species can have proinﬂammatory properties [75]. Addi-
tionally, experiments conducted at supra-physiological O2 ten-
sions may yield misleading results, as high O2 concentrations
increase production of proinﬂammatory oxidized sulfur species
[53,75]. In order to move H2S from the ‘‘bench to the bedside’’,
comprehensive pharmacological studies are needed, which
focus on routes of administration, type of donor compounds
used, kinetics and magnitude of H2S release, timing of the
intervention, physiologically and pathologically relevant O2
tensions, and the type of inﬂammatory condition being
addressed.10. Hydrogen sulﬁde and cytoprotection
As mentioned in earlier sections, the therapeutic window for
effective H2S treatment is likely very narrow because H2S is a
potent inhibitor of mitochondrial respiration. Therefore, several
pharmacological factors including dose, route of administration,
and timing of H2S exposure must be carefully considered when
using H2S as a therapy. In the following paragraphs, select
examples from the literature are presented showing cytoprotec-
tive effects of H2S and other sulﬁde-based compounds in models
of cardiovascular disease.11. Cardiovascular disease
Studies show decreased plasma levels of H2S in atherosclerosis
models [51,77]. Furthermore, endogenous production of H2S in
sclerotic aortic tissues is impaired due to decreased expression of
CGL in VSMCs [78]. Conversely, in cases of H2S over-production
(e.g., Trisomy 21) progression of atherosclerosis is slower [79].
H2S may slow disease progression of atherosclerosis by inhibiting
several elements of foam cell formation. Macrophages incubated
with oxidized lipoprotein (oxLDL) show decreased intracellular
lipid accumulation when treated with H2S, whereas inhibiting
endogenous H2S production exacerbates lipid accumulation [80].
Expression of scavenger receptors responsible for oxLDL accumu-
lation was also decreased with H2S treatment [80]. Using apoli-
poprotein E knockout mice, H2S decreases expression of adhesion
molecules, thus preventing the recruitment of macrophages into
the vascular intima, which is accompanied by a reduction in pro-
inﬂammatory cytokines [2]. In atherosclerotic plaques, VSMCs
proliferate and assume a ﬁbrogenic phenotype, contributing to
vessel occlusion. H2S, at high concentrations, prevents VSMC
proliferation [81]. Together, these results support the concept
that sulﬁde-based therapies attenuate some of the early meta-
bolic changes that contribute to cardiovascular disease. What isnot known is whether H2S is efﬁcacious in end stage cardiovas-
cular disease.
Considerable work has also focused on the impact sulﬁde-based
therapies have in ameliorating cardiac ischemia-reperfusion injury.
Lefer and colleagues have shown that pretreatment with sodium
sulﬁde (Na2S) before cardiac ischemia-reperfusion reduces infarct
size and improves overall cardiac function [3,82,83]. There are
several proposed mechanisms underlying this protective effect.
First, H2S up-regulates anti-oxidant response element (ARE) genes
by inducing the translocation of Nrf-2 to the nucleus [84]. This
increases GSH and expression of antioxidant proteins such as heme
oxygenase-1, glutathione S-transferase, and thioredoxin-1 [84].
Second, H2S acts through Akt-dependent pro-survival pathways
to prevent caspase 3 activation and association of pro-apoptotic
proteins to mitochondria that are necessary for mitochondrial
permeability pore formation and cytochrome c release [85]. The
effects of H2S on the mitochondrion are likely central to overall
cardiomyocyte protection [86], which may also involve activation
of KATP channels [87]. While some groups attribute the cytoprotec-
tion to mitochondrial KATP channels, others using organelle-speciﬁc
KATP channel blockers show that cytoprotection is due to effects on
sarcolemmal channels [88].
Interestingly, daily H2S administration for several months
prevented perivascular ﬁbrosis and subsequent arteriole occlu-
sion in spontaneously hypertensive rats. [89], suggesting that H2S
administration may prevent pathogenic vascular remodeling. H2S
prevents thickening of damaged arterial intima and medial
thickening of intramyocardial coronary arterioles [90]. Finally,
H2S induces neovascularization in models of chronic ischemia
[64]. This molecular action of H2S may be highly important
following acute cardiac ischemia, as maintenance of a highly
vascularized myocardium is required for proper organ function.
These select ﬁndings, when taken together, demonstrate the
promise of H2S as a treatment for chronic cardiovascular diseases,
as well as, in the emergency room for patients suffering from
cardiac arrest.12. Summary
The actions of H2S described in this review highlight its ability
to function in redox biology and cell signaling. With a pKa of 6.9,
both protonated and anion forms of H2S are present at physiolo-
gical pH. This allows for the free diffusion of H2S to all cellular
compartments. Because H2S-producing enzymes play a diverse
role in the larger sulfur cycle of the cell, the production of H2S is
dependent on cellular redox status. During conditions of oxidative
stress the amount of reduced substrates like cysteine available for
H2S production may be limited. Moreover, steady state H2S
concentrations will be determined by H2S consumption pathways
that are redox sensitive as well. Importantly, O2 being an
antagonist of H2S will also accelerate H2S oxidation and inhala-
tion of 100% O2 is, in fact, a treatment for H2S gas inhalation. Also
highlighted herein, is the impact of O2 tension on the biological
actions and outcomes of H2S. For example, H2S-mediated vasodi-
lation is observed at physiological O2 concentrations, whereas at
vasoconstriction occurs at hyperoxia (Fig. 4). These same patterns
can also be extended to other biological processes such as
inﬂammation and angiogenesis (Fig. 4). Furthermore, many of
the cytoprotective actions of H2S are triggered by and act to
attenuate oxidative stress as exempliﬁed by the ability of H2S to
induce the expression of antioxidant enzymes during myocardial
ischemia-reperfusion. In conclusion, investigation of the redox
biology of H2S will not only increase understanding of its role in
human physiology, but its potential therapeutic role in patholo-
gies where oxidative stress is central to the disease process.
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